Mechanism of action
NAD+ is the central electron acceptor of catabolic metabolism: in the NAD+/NADH redox cycle it accepts reducing equivalents from glycolysis, beta-oxidation and the citric acid cycle and releases them again at mitochondrial Complex I of the respiratory chain. Beyond redox chemistry, NAD+ is consumed by signalling enzymes. Sirtuins (SIRT1 to SIRT7, NAD+-dependent class III deacylases, with additional enzymatic activities in some family members) cleave off nicotinamide during catalysis and modulate PGC-1alpha-, FOXO- and p53-dependent programmes; PARP1 uses NAD+ for poly-ADP-ribosylation in the DNA damage response; the ectoenzymes CD38 and CD157 as well as SARM1 hydrolyse NAD+ and lower the cellular pool. The pool is replenished mainly through the salvage pathway (NAMPT, NMNAT1 to NMNAT3, starting from nicotinamide, NR and NMN) and de novo from tryptophan via the kynurenine pathway. This compartmentalisation is why the literature does not equate extracellular NAD+ exposure with a direct rise in the intracellular pool.
State of evidence
The mechanistic basis is broad: in vitro work and rodent models describe an age-associated decline in tissue NAD+ and metabolic effects of raising the pool, for example through CD38 inhibition. In humans, however, controlled data mostly cover the precursors NR and NMN rather than NAD+ itself; the NADPARK trial was a randomised, double-blind phase 1 study of NR in Parkinson's disease, designed for safety, target engagement and feasibility rather than clinical efficacy. For systemically administered NAD+ there is one small open-label pilot investigation of the plasma and urine NAD+ metabolome during a six-hour infusion, with a very small sample size (eight participants in the infusion arm, three in a saline control arm) and no blinding. This small metabolome study provides neither a reliable general elimination half-life for administered NAD+ nor evidence of clinical efficacy. Cellular uptake and degradation routes of extracellular NAD+, dose-response relationships and long-term data remain open. The cited reports provide no phase 3 outcome evidence for administered NAD+ and do not establish authorization of a particular product. Precursor and NAD+ literature are not interchangeable.
Questions about the research
- What is NAD+ studied for in research?
- NAD+ is studied as a redox cofactor and as a substrate of NAD+-consuming enzymes, mainly in the context of mitochondrial function, ageing metabolism, the DNA damage response and neurodegeneration. A recurring theme is the age-associated decline of the NAD+ pool seen in tissue models and the question of whether and how it can be influenced. These are mechanistic questions and say nothing about clinical benefit.
- What is the state of the evidence on NAD+?
- The preclinical literature is extensive, whereas human data are thin and largely indirect: controlled studies mostly involve the precursors NR and NMN, such as a randomised phase 1 trial of NR. For systemically administered NAD+ itself there is essentially one small, open-label pilot investigation of the plasma and urine metabolome during an infusion. No robust efficacy or safety conclusions follow from this, and precursor data must not be transferred to NAD+.
Sources
- Rajman, Chwalek and Sinclair, Cell Metab 2018, review of NAD-related biology and therapeutic researchDOI: 10.1016/j.cmet.2018.02.011PMID: 29514064
- Yoshino, Baur and Imai, Cell Metab 2018, review of NAD intermediates NR and NMNDOI: 10.1016/j.cmet.2017.11.002PMID: 29249689
- Brakedal et al., Cell Metab 2022 (NADPARK)DOI: 10.1016/j.cmet.2022.02.001PMID: 35235774
- Tarrago et al., Cell Metab 2018DOI: 10.1016/j.cmet.2018.03.016PMID: 29719225
- Grant et al., Front Aging Neurosci 2019DOI: 10.3389/fnagi.2019.00257PMID: 31572171
